您當(dāng)前的位置：檢測(cè)資訊 > 監(jiān)管召回
嘉峪檢測(cè)網(wǎng) 2024-11-14 08:16
摘 要
美國(guó)FDA于2024年03月22日對(duì)Antaria Pty.Ltd.簽發(fā)了警告信，主要包括了如下重大缺陷：
超標(biāo)結(jié)果(OOS)重復(fù)發(fā)生，調(diào)查未確定根本原因，糾正預(yù)防措施無(wú)法確認(rèn)有效性。
警告信中提到，該公司對(duì) API 實(shí)驗(yàn)室測(cè)試（包括含量和熾灼失重(LOI) 測(cè)試）期間獲得的大量 OOS 結(jié)果缺乏充分的調(diào)查和糾正措施。根本原因未得到明確定義，且未充分記錄，并且質(zhì)量部門 (QU) 放行了 OOS 結(jié)果批次。
企業(yè)的回復(fù)沒(méi)有得到FDA認(rèn)可，主要體現(xiàn)在沒(méi)有描述對(duì)所有調(diào)查的根本原因分析和糾正措施充分性的整體審查，沒(méi)有通知收到 OOS 批次的客戶進(jìn)行檢測(cè)，也沒(méi)有對(duì)留樣樣品進(jìn)行回顧性評(píng)估。同時(shí)，給出了需要進(jìn)一步開展的工作與需要提供的資料，值的充分研究和學(xué)習(xí)。（該條缺陷很有代表性，OOS調(diào)查是企業(yè)的難點(diǎn)，F(xiàn)DA不僅闡明了具體問(wèn)題，并且給出了解題思路，值得深入研究和學(xué)習(xí)）
產(chǎn)品檢測(cè)的分析方法未進(jìn)行驗(yàn)證，無(wú)法確認(rèn)企業(yè)自身的分析方法相當(dāng)于或優(yōu)于USP方法。
警告信提到，該公司未能按照美國(guó)藥典 (USP) 專論現(xiàn)行版本對(duì)產(chǎn)品進(jìn)行適當(dāng)?shù)姆治鰷y(cè)試（含量和熾灼失重），也沒(méi)有數(shù)據(jù)支持其測(cè)試方法相當(dāng)于或優(yōu)于 USP 方法。（既沒(méi)有按USP方法執(zhí)行測(cè)試，又沒(méi)有進(jìn)行相關(guān)分析方法驗(yàn)證，與USP的方法進(jìn)行對(duì)比研究）
實(shí)驗(yàn)室控制記錄信息不完整，缺少部分檢測(cè)過(guò)程中的信息數(shù)據(jù)。
警告信中提到，該公司未能在實(shí)驗(yàn)室記錄中納入所有實(shí)驗(yàn)室分析項(xiàng)目的完整數(shù)據(jù)，并且依賴不完整的信息來(lái)確定產(chǎn)品是否符合質(zhì)量標(biāo)準(zhǔn)。例如，缺少在 API 測(cè)試期間使用的儲(chǔ)備溶液、樣品溶液、稀釋劑、流動(dòng)相和試劑的制備記錄。還未能記錄進(jìn)行分析測(cè)試時(shí)所使用的儀器和設(shè)備。（該問(wèn)題在國(guó)內(nèi)的公司還是比較常見的，體現(xiàn)了實(shí)驗(yàn)室記錄設(shè)計(jì)存在不足，違背了記錄可追溯性的原則）
未能設(shè)計(jì)充分書面的、持續(xù)的穩(wěn)定性測(cè)試程序來(lái)監(jiān)控 API 的穩(wěn)定性特性，并使用結(jié)果來(lái)確認(rèn)適當(dāng)?shù)拇鎯?chǔ)條件和復(fù)驗(yàn)期或有效期。
警告信中提到，該公司的穩(wěn)定性計(jì)劃不夠充分。在2019 年、2020 年或 2021 年生產(chǎn)的API，未能進(jìn)行年度至少一批穩(wěn)定性考察。穩(wěn)定性程序缺乏有關(guān)適當(dāng)測(cè)試方法的具體要求。此外，穩(wěn)定性研究?jī)H包括 2015 年生產(chǎn)的批次，并且僅在 2022 年建立了年度持續(xù)穩(wěn)定性計(jì)劃。
該公司的回復(fù)是不充分的，因?yàn)闆](méi)有討論對(duì)流通中已經(jīng)生產(chǎn)而未經(jīng)適當(dāng)穩(wěn)定性測(cè)試的 API 批次的回顧性審查。（不能僅僅是“我目前符合要求”了，而且要證明與確認(rèn)之前的做法是否已經(jīng)產(chǎn)生了風(fēng)險(xiǎn)?。?/span>
從缺陷可以看到此封警告信的關(guān)注點(diǎn)主要為超標(biāo)結(jié)果調(diào)查和糾正措施實(shí)施的有效性、實(shí)驗(yàn)室控制模塊工作存在不足，無(wú)法確保銷售產(chǎn)品的質(zhì)量可控。
【基礎(chǔ)信息:】
Posted Date：2024.4.9
Letter lssue Date：2024.3.22
FEI：3025978151
Firm name：Antaria Pty.Ltd.
Type establishment inspected：Drug Manufacturing Facility
Investigator：N/A
警告信正文
The U.S.Food and Drug Administration (FDA) inspected your drug manufacturing facility, Antaria Pty.Ltd., FEI 3025978151, at 81 Shettleston St, Units 1 & 2 Rocklea, Queensland, Australia, from November 13 to 17, 2023.
美國(guó)食品藥品監(jiān)督管理局 (FDA) 于2023 年11月13日至17日檢查了你們位于81 Shettleston St, Units 1 & 2 Rocklea, Queensland, Australia的藥品生產(chǎn)工廠Antaria PtyLtd.，F(xiàn)EI 3025978151。
This warning letter summarizes significant deviations from Current Good Manufacturing Practice (CGMP) for active pharmaceutical ingredients (API)
本警告信總結(jié)了原料藥（API）現(xiàn)行良好生產(chǎn)規(guī)范（CGMP）的重大偏差。
Because your methods, facilities, or controls for manufacturing, processing, packing, or holding do not conform to CGMP, your API are adulterated within the meaning of section 501(a)(2)(B) of the Federal Food, Drug, and Cosmetic Act (FD&C Act), 21 U.S.C.351(a)(2)(B).
由于你們的生產(chǎn)、工藝、包裝或貯存的方法、設(shè)施或控制不符合 CGMP， 依據(jù)《聯(lián)邦食品、藥品和化妝品法案》（FD&C 法案）501(a)(2)(B) 節(jié)、21 U.S.C. 351(a)(2)(B) 的規(guī)定，你們的 API被判定為摻假。
We reviewed your December 7, 2023 response to our Form FDA 483 in detail and acknowledge receipt of your subsequent correspondence.
我們?cè)敿?xì)審查了你們公司于 2023 年 12 月 7 日對(duì)我們的 FDA 483 表的回復(fù)，并確認(rèn)收到了你們后續(xù)的應(yīng)對(duì)。
During our inspection, our investigator observed specific deviations including, but not limited to, the following.
在檢查過(guò)程中，我們的調(diào)查人員發(fā)現(xiàn)的具體偏差包括但不限于以下內(nèi)容。
1.Failure to adequately investigate and document out-of-specification results and implement appropriate corrective actions.
未能充分調(diào)查和記錄超標(biāo)結(jié)果(OOS)并實(shí)施適當(dāng)?shù)募m正措施。
Your firm manufactures API (b)(4) USP, labeled in part to be the active ingredient used in (b)(4).You failed to adequately investigate out-of-specification (OOS) test results.Specifically, your firm lacked adequate investigations and corrective actions for numerous OOS results obtained during laboratory testing of your API, including assay and loss on ignition (LOI) testing.The root causes were not clearly defined nor adequately documented, and lots with OOS results were released by your quality unit (QU).
你公司生產(chǎn) API (b)(4) USP，部分標(biāo)簽顯示其為 (b)(4) 中使用的活性成分。你們未能充分調(diào)查超標(biāo)（OOS）的測(cè)試結(jié)果。具體來(lái)說(shuō)，你們公司對(duì)在 API 實(shí)驗(yàn)室測(cè)試（包括含量和熾灼失重(LOI) 測(cè)試）期間獲得的大量 OOS 結(jié)果缺乏充分的調(diào)查和糾正措施。根本原因未得到明確定義，且未充分記錄，并且你們的質(zhì)量部門 (QU) 放行了 OOS 結(jié)果批次。
In your response, you state that staff turnover and insufficient staff training attributes to the lack of competency in good laboratory practices.Additionally, you state that you will revise your OOS procedures.You also state that you will review historical LOI OOS to identify a root cause and retrain your laboratory staff. Your response is inadequate because you failed to describe a holistic review of all investigations’ root cause analyses and corrective actions for adequacy.In addition, you did not inform your customers who received OOS lots for assay nor perform a retrospective assessment of retain samples.
在你們的回復(fù)中，你們指出員工流動(dòng)和員工培訓(xùn)不足導(dǎo)致缺乏良好的實(shí)驗(yàn)室實(shí)踐能力。此外，你們表示將修改您的 OOS 程序。你們還表示，你們將回顧歷史LOI OOS數(shù)據(jù)，以識(shí)別根本原因并重新培訓(xùn)你們的實(shí)驗(yàn)室工作人員。你們的回復(fù)不充分，因?yàn)槟銈儧](méi)有描述對(duì)所有調(diào)查的根本原因分析和糾正措施充分性的整體審查。此外，你們沒(méi)有通知收到 OOS 批次的客戶進(jìn)行檢測(cè)，也沒(méi)有對(duì)留樣樣品進(jìn)行回顧性評(píng)估。
Inadequate investigations can lead to unidentified root causes, ineffective corrective action and preventive action (CAPA), and recurring problems that compromise the ability to manufacture safe and effective drugs.
調(diào)查不充分可能導(dǎo)致無(wú)法確定根本原因、無(wú)效的糾正措施和預(yù)防措施 (CAPA) 以及影響生產(chǎn)安全有效藥物能力的反復(fù)出現(xiàn)的問(wèn)題。
For more information about handling OOS results and documentation of your investigations, please refer to the FDA guidance for industry publication Investigating Out-of-Specification at https://www.fda.gov/media/158416/download
有關(guān)處理 OOS 結(jié)果和調(diào)查文件的更多信息，請(qǐng)參閱 FDA 行業(yè)出版物《超標(biāo)調(diào)查》指南，網(wǎng)址為 https://www.fda.gov/media/158416/download
In response to this letter, provide:
在回復(fù)此信時(shí)，請(qǐng)?zhí)峁?/span>
A retrospective, independent review of all invalidated OOS (including in-process and release/stability testing) results for U.S. products irrespective of whether the batch was ultimately distributed in the United States and a report summarizing the findings of the analysis, including the following for each OOS:
對(duì)美國(guó)注冊(cè)的產(chǎn)品所有無(wú)效的OOS（包括中控和放行/穩(wěn)定性測(cè)試）結(jié)果進(jìn)行回顧性的、獨(dú)立的審查，無(wú)論該批次最終是否在美國(guó)分銷，并提交一份總結(jié)分析結(jié)果的報(bào)告，包括針對(duì)每項(xiàng) OOS 的以下內(nèi)容：
※ Determine whether the scientific justification and evidence relating to the invalidated OOS result conclusively or inconclusively demonstrates causative laboratory error.
對(duì)于無(wú)效的 OOS 結(jié)果，確定相關(guān)的科學(xué)依據(jù)和證據(jù)是否確鑿或不確鑿地證明了導(dǎo)致實(shí)驗(yàn)室錯(cuò)誤的原因。
※ For investigations that conclusively establish laboratory root cause, provide rationale, and ensure that all other laboratory methods vulnerable to the same or similar root cause are identified for remediation.
對(duì)于最終確定實(shí)驗(yàn)室根本原因的調(diào)查，提供合理依據(jù)，并確保被認(rèn)為所有其他易受相同或類似根本原因影響的實(shí)驗(yàn)室方法已進(jìn)行補(bǔ)救。
※ For all OOS results found by the retrospective review to have an inconclusive or no root cause identified in the laboratory, include a thorough review of production (e.g., batch manufacturing records, adequacy of the manufacturing steps, suitability of equipment/facilities, variability of raw materials, process capability, deviation history, complaint history, batch failure history).Provide a summary of potential manufacturing root causes for each investigation, and any manufacturing operation improvements.
對(duì)于回顧性審查發(fā)現(xiàn)的所有 OOS 結(jié)果，如果其在實(shí)驗(yàn)室中沒(méi)有確定的根本原因或沒(méi)有發(fā)現(xiàn)根本原因，則需要對(duì)生產(chǎn)進(jìn)行徹底審查（例如，批生產(chǎn)記錄、生產(chǎn)步驟的充分性、設(shè)備/設(shè)施的適用性、原材料的變化、過(guò)程能力、偏差歷史、投訴歷史、批次不合規(guī)歷史）。匯總每次調(diào)查的潛在生產(chǎn)根本原因和任何的生產(chǎn)操作改進(jìn)。
A comprehensive, independent assessment of your overall system for investigating deviations, discrepancies, complaints, OOS results, and failures. Provide a detailed action plan to remediate this system.Your action plan should include, but not be limited to, significant improvements in investigation competencies, scope determination, root cause evaluation, CAPA effectiveness, QU oversight, and written procedures.Address how your firm will ensure all phases of investigations are appropriately conducted.
對(duì)你們的整個(gè)系統(tǒng)進(jìn)行全面、獨(dú)立的評(píng)估，以調(diào)查偏差、異常情況、投訴、OOS 結(jié)果和不合格事件。提供詳細(xì)的行動(dòng)計(jì)劃來(lái)改進(jìn)該系統(tǒng)。你們的行動(dòng)計(jì)劃應(yīng)包括但不限于調(diào)查能力、范圍確定、根本原因評(píng)估、CAPA 有效性、QU 監(jiān)督和書面程序方面的重大改進(jìn)。說(shuō)明你們公司將如何確保調(diào)查的所有階段均得到適當(dāng)執(zhí)行。
2.Failure to ensure that, for each batch of API, appropriate laboratory tests are conducted to determine conformance to specifications.
未能確保對(duì)每批 API 進(jìn)行適當(dāng)?shù)膶?shí)驗(yàn)室測(cè)試以確定符合質(zhì)量標(biāo)準(zhǔn)。
Based on review of your laboratory results, you failed to appropriately perform analytical testing (assay and LOI) of your (b)(4) USP in accordance to the current version of United States Pharmacopeia (USP) monograph, nor did you have data to support that your test method was equivalent or better than the USP method.In your response, you state that you will revise your (b)(4) USP assay and LOI test methods to better align with the USP.
根據(jù)對(duì)你們實(shí)驗(yàn)室結(jié)果的審查，你們未能按照美國(guó)藥典 (USP) 專論現(xiàn)行版本對(duì)你們的 (b)(4) USP 進(jìn)行適當(dāng)?shù)姆治鰷y(cè)試（含量和熾灼失重），也沒(méi)有數(shù)據(jù)支持你們的測(cè)試方法相當(dāng)于或優(yōu)于 USP 方法。在你們的回復(fù)中，你們表示將修改 (b)(4) USP 的含量和 LOI 檢測(cè)方法，以更好地與 USP 保持一致。
Without adequate testing, there is no scientific evidence to assure that your APIs conform to appropriate specifications before release.
如果沒(méi)有經(jīng)過(guò)充分的測(cè)試，就沒(méi)有科學(xué)證據(jù)來(lái)保證您的 API 在放行之前符合適當(dāng)?shù)馁|(zhì)量標(biāo)準(zhǔn)。
See FDA’s guidance document, Analytical Procedures and Methods Validation for Drugs and Biologics, for general principles and approaches that FDA considers appropriate elements of analytical method validation at https://www.fda.gov/media/87801/download.
請(qǐng)參閱 FDA 的指導(dǎo)文件《藥品和生物制品的分析程序和方法驗(yàn)證》，了解 FDA 認(rèn)為適合分析方法驗(yàn)證要素的一般原則和方法，網(wǎng)址為https://www.fda.gov/media/87801/download
In response to this letter provide:
在回復(fù)此信時(shí)請(qǐng)?zhí)峁?/span>
A list of chemical and microbial test methods and specifications used to analyze each lot of your API before making a lot disposition decision, and the associated written procedures.
在做出批次處置決定之前，用于分析每批 API 的化學(xué)和微生物測(cè)試方法和質(zhì)量標(biāo)準(zhǔn)的列表，以及相關(guān)的書面程序。
A comprehensive, independent assessment of your laboratory practices, procedures, methods, equipment, documentation, and analyst competencies. Based on this review, provide a detailed plan to remediate and evaluate the effectiveness of your laboratory system.
對(duì)你們的實(shí)驗(yàn)室實(shí)踐、程序、方法、設(shè)備、文檔和分析人員能力進(jìn)行全面、獨(dú)立的評(píng)估。根據(jù)此審查，提供詳細(xì)的計(jì)劃來(lái)改進(jìn)并評(píng)估你們公司實(shí)驗(yàn)室系統(tǒng)的有效性。
3.Failure to have laboratory control records that include complete data derived from all laboratory tests conducted to ensure your API complies with established specifications and standards.
未能提供包含所有實(shí)驗(yàn)室測(cè)試的完整數(shù)據(jù)的實(shí)驗(yàn)室控制記錄，以確保你們的 API 符合既定的規(guī)范和質(zhì)量標(biāo)準(zhǔn)。
You failed to include complete data in your laboratory records for all laboratory analyses, and accordingly relied on incomplete information to determine whether your (b)(4) USP met established specifications.For example, you lacked documentation of the preparation of stock solutions, sample solutions, diluents, mobile phases, and reagents used during testing of your API.You also failed to document the instruments and equipment used when performing analytical testing.
你們未能在實(shí)驗(yàn)室記錄中納入所有實(shí)驗(yàn)室分析項(xiàng)目的完整數(shù)據(jù)，并且依賴不完整的信息來(lái)確定你們的 (b)(4) USP 是否符合既定的質(zhì)量標(biāo)準(zhǔn)。例如，你們?nèi)鄙僭?API 測(cè)試期間使用的儲(chǔ)備溶液、樣品溶液、稀釋劑、流動(dòng)相和試劑的制備記錄。你們還未能記錄進(jìn)行分析測(cè)試時(shí)所使用的儀器和設(shè)備。
In your response, you acknowledge that your laboratory records lack complete testing information.You also state that you update your worksheets to record pertinent information.Your response is inadequate because it does not address the overall lack of traceability of previous analytical data, nor does it include a comprehensive strategy to confirm the validity of the previous analytical data used to release your (b)(4) USP.
在你們的回復(fù)中，承認(rèn)你們的實(shí)驗(yàn)室記錄缺乏完整的測(cè)試信息。你們還聲明你們更新了工作表以記錄相關(guān)信息。你們的回復(fù)是不充分的，因?yàn)樗鼪](méi)有解決先前分析數(shù)據(jù)整體缺乏可追溯性的問(wèn)題，也沒(méi)有包括一個(gè)全面的策略來(lái)證實(shí)用于放行你們 (b)(4) USP 的先前分析數(shù)據(jù)的有效性。
Without adequate documentation of analytical tests and equipment used, you lack basic data to support that each API product batch conforms to appropriate specifications before release and distribution.
如果沒(méi)有足夠的分析測(cè)試和所用設(shè)備的記錄，你們將缺乏基本數(shù)據(jù)來(lái)支持每個(gè)批次API 產(chǎn)品在放行和分銷之前符合適當(dāng)?shù)馁|(zhì)量標(biāo)準(zhǔn)。
In response to this letter provide a complete assessment of documentation systems used throughout your manufacturing and laboratory operations to determine where documentation practices are insufficient.Include a detailed CAPA plan that comprehensively remediates your firm’s documentation practices to ensure you retain attributable, legible, complete, original, accurate, contemporaneous records throughout your operation.
在回復(fù)此信時(shí)，請(qǐng)?zhí)峁?duì)你們整個(gè)生產(chǎn)和實(shí)驗(yàn)室操作過(guò)程中使用的文件系統(tǒng)的完整評(píng)估，以確定哪些地方的文檔記錄不足。包括一份詳細(xì)的 CAPA 計(jì)劃，全面補(bǔ)救你們公司的文件記錄規(guī)范性，以確保你們?cè)谡麄€(gè)運(yùn)營(yíng)過(guò)程中保留可追溯、清晰、完整、原始、準(zhǔn)確、同步的記錄。
4.Failure to design an adequate documented, on-going stability testing program to monitor the stability characteristics of API and to use the results to confirm appropriate storage conditions and retest or expiry dates.
未能設(shè)計(jì)充分書面的、持續(xù)的穩(wěn)定性測(cè)試程序來(lái)監(jiān)控 API 的穩(wěn)定性特性，并使用其結(jié)果來(lái)確認(rèn)適當(dāng)?shù)拇鎯?chǔ)條件和復(fù)驗(yàn)期或有效期。
Your firm’s stability program is inadequate.Your firm failed to place at least one lot of your API manufactured in 2019, 2020, or 2021 on stability annually.
你們公司的穩(wěn)定性計(jì)劃不夠充分。你們公司在2019 年、2020 年或 2021 年生產(chǎn)的API，未能進(jìn)行年度至少一批穩(wěn)定性考察。
In your response, you acknowledge that your stability procedure lacks specificity regarding appropriate testing.Additionally, you acknowledge that your stability study only consists of lots manufactured in 2015 and that you only establish your annual, ongoing stability program in 2022.Your response is inadequate because you did not discuss a retrospective review of API lots in distribution that were manufactured without appropriate stability testing
在你們的回復(fù)中，你們承認(rèn)你們的穩(wěn)定性程序缺乏有關(guān)適當(dāng)測(cè)試方法的具體要求。此外，你們承認(rèn)，你們的穩(wěn)定性研究?jī)H包括 2015 年生產(chǎn)的批次，并且你們僅在 2022 年建立了年度持續(xù)穩(wěn)定性計(jì)劃。你們的回復(fù)是不充分的，因?yàn)槟銈儧](méi)有討論對(duì)流通中已經(jīng)生產(chǎn)而未經(jīng)適當(dāng)穩(wěn)定性測(cè)試的 API 批次的回顧性審查。
Without an adequate stability program, you cannot ensure that your APIs meet established specifications and all pre-determined quality criteria throughout the APIs’ assigned shelf-life.
如果沒(méi)有適當(dāng)?shù)姆€(wěn)定性程序，你們就無(wú)法確保你們的 API 在指定的貨架期內(nèi)符合既定的質(zhì)量標(biāo)準(zhǔn)和所有預(yù)定的質(zhì)量要求。
In response to this letter provide:
在回復(fù)此信時(shí)請(qǐng)?zhí)峁?/span>
A comprehensive, independent assessment and CAPA plan to ensure the adequacy of your stability program. Your remediated program should include, but not be limited to:
全面、獨(dú)立的評(píng)估和 CAPA 計(jì)劃可確保你們的穩(wěn)定性計(jì)劃的充分性。你們的補(bǔ)救計(jì)劃應(yīng)包括但不限于：
※ Stability-indicating methods
穩(wěn)定性指示方法
※ Stability studies for each drug product in its marketed container-closure system before distribution is permitted.
在允許分銷之前，對(duì)每種藥品在其上市容器封閉系統(tǒng)中進(jìn)行穩(wěn)定性研究。
※ An ongoing program in which representative batches of each product are added each year to the program to determine if the shelf-life claim remains valid.
這是一項(xiàng)持續(xù)進(jìn)行的計(jì)劃，每年都會(huì)將每種產(chǎn)品的代表性批次添加到計(jì)劃中，以確定聲稱的貨架期是否仍然有效。
※ Detailed definition of the specific attributes to be tested at each station (timepoint).
詳細(xì)定義每個(gè)站點(diǎn)（時(shí)間點(diǎn)）要測(cè)試的具體屬性。
All procedures that describe these and other elements of your remediated stability program.
描述這些內(nèi)容以及穩(wěn)定性補(bǔ)救計(jì)劃的其他要素的所有程序。
Additional API CGMP Guidance
其他 API CGMP 指南
FDA considers the expectations outlined in ICH Q7 when determining whether API are manufactured in conformance with CGMP.See FDA’s guidance document Q7 Good Manufacturing Practice Guidance for Active Pharmaceutical Ingredients for guidance regarding CGMP for the manufacture of API at https://www.fda.gov/media/71518/download.
在確定 API 是否符合 CGMP條件下生產(chǎn)時(shí)，F(xiàn)DA 會(huì)考慮 ICH Q7 中概述的期望。有關(guān) API 制造的 CGMP 指導(dǎo)，請(qǐng)參閱 FDA 指南 Q7原料藥良好生產(chǎn)規(guī)范指南，網(wǎng)址為https://www.fda.gov/media/71518/download
Conclusion
結(jié)論
The deviations cited in this letter are not intended to be an all-inclusive list of deviations that exist at your facility.You are responsible for investigating and determining the causes of any deviations and for preventing their recurrence or the occurrence of other deviations.
本信中引用的偏差并非你們工廠存在的所有偏差的完整列表。你們公司有責(zé)任調(diào)查并確定任何偏差的原因，并防止其再次發(fā)生或發(fā)生其他偏差。
Correct any deviations promptly.FDA may withhold approval of new applications or supplements listing your firm as a drug manufacturer until any deviations are completely addressed and we confirm your compliance with CGMP.We may re-inspect to verify that you have completed corrective actions to any deviations.
及時(shí)糾正任何偏差。FDA 可能會(huì)拒絕批準(zhǔn)將你們公司列為藥品制造商的新申請(qǐng)或補(bǔ)充申請(qǐng)，直到所有偏差得到徹底解決且我們確認(rèn)你們公司符合 CGMP。我們可能會(huì)重新檢查以驗(yàn)證你公司是否完成所有偏差的糾正措施。
Failure to address any violations may also result in the FDA refusing admission of articles manufactured at Antaria Pty.Ltd.81 Shettleston St, Units 1 & 2 Rocklea, Queensland, Australia into the United States under section 801(a)(3) of the FD&C Act, 21 U.S.C.381(a)(3).Articles under this authority that appear to be adulterated may be detained or refused admission, in that the methods and controls used in their manufacture do not appear to conform to CGMP within the meaning of section 501(a)(2)(B) of the FD&C Act, 21 U.S.C.351(a)(2)(B).
根據(jù)聯(lián)邦食品、藥品和化妝品法案第 801(a)(3) 節(jié),21 U.S.C. 381(a)(3)，未能解決所有違規(guī)行為也可能導(dǎo)致 FDA 拒絕接納 Antaria Pty.Ltd.81 Shettleston St, Units 1 & 2 Rocklea, Queensland, Australia生產(chǎn)的物品到美國(guó)。根據(jù)該授權(quán)，如果物品疑似摻假，則可能被扣留或拒絕入境。因?yàn)槠渲圃爝^(guò)程中使用的方法和控制疑似不符合 FD&C 法案（21 U.S.C. 351(a)(2)(B)）第 501(a)(2)(B) 條 CGMP 的規(guī)定。
This letter notifies you of our findings and provides you an opportunity to address the above deficiencies.After you receive this letter, respond to this office in writing within 15 working days.Specify what you have done to address any deviations and to prevent their recurrence.In response to this letter, you may provide additional information for our consideration as we continue to assess your activities and practices.If you cannot complete corrective actions within 15 working days, state your reasons for delay and your schedule for completion.
這封信函告知你們我們的調(diào)查結(jié)果并為您提供解決上述缺陷的機(jī)會(huì)。收到此信后，請(qǐng)?jiān)?5個(gè)工作日內(nèi)以書面形式回復(fù)本辦公室。詳細(xì)說(shuō)明你們?yōu)榻鉀Q偏差并防止其再次發(fā)生所做的努力。在回復(fù)此信時(shí)，你們可以提供更多信息供我們考慮，因?yàn)槲覀儠?huì)繼續(xù)評(píng)估你們的活動(dòng)和做法。如果您無(wú)法在 15 個(gè)工作日內(nèi)完成糾正措施，請(qǐng)說(shuō)明延遲的原因和完成計(jì)劃。
來(lái)源：科威利華
關(guān)于我們 聯(lián)系我們 營(yíng)業(yè)執(zhí)照 全國(guó)服務(wù)電話：400-818-0021 嘉峪檢測(cè)版權(quán)所有 備案號(hào)：京ICP備14047019號(hào)-2 
京公網(wǎng)安備11010802046783號(hào)
